The Hancock pericardial xenograft: incidence of early mechanical failures at a medium-term follow-up.
The Hancock pericardial xenograft has been used in our Institution since August 1981 as an alternative to porcine bioprostheses. Up to July 1984, 97 Hancock pericardial xenografts have been implanted in 84 patients; of 76 operative survivors with a mean age of 55.2 +/- 13 years (range 13-75 years), 50 had undergone aortic valve replacement, 16 mitral valve replacement and 10 mitral-aortic valve replacement. Follow-up ranged from 0.5 to 5.2 years with a cumulative duration of 239 patient/years and is 99% complete. Actuarial survival is 92% +/- 4% for patients with aortic valve replacement and 84% +/- 10% for patients with mitral valve replacement at 5 years, and 77% +/- 14% for those with mitral-aortic valve replacement at 4 years. Thromboembolic episodes occurred in 2 patients (1 after aortic and 1 after mitral valve replacement). The actuarial freedom from emboli is 100% for patients with mitral-aortic valve replacement at 4 years, and 96% +/- 3% for patients with aortic and 93% +/- 6% for patients with mitral valve replacement at 5 years. Reoperation was performed in 13 patients (9 aortic, 2 mitral and 2 mitral-aortic valve replacements), because of endocarditis in 3 (2 aortic and 1 mitral valve replacement), paravalvular leak in 1 (aortic valve replacement), and primary tissue failure in 9 (6 aortic, 1 mitral and 2 mitral-aortic valve replacements). Actuarial freedom from primary tissue failure is 72% +/- 9% for aortic and 83% +/- 8% for mitral Hancock pericardial xenografts at 5 years. Eleven xenografts explanted because of primary tissue failure were studied pathologically.(ABSTRACT TRUNCATED AT 250 WORDS)
Bortolotti
U
U
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.
Milano
A
A
Mazzucco
A
A
Guerra
F
F
Valente
M
M
Thiene
G
G
Talenti
E
E
Gallucci
V
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D001021:Aortic Valve / Q000601:surgery; D001705:Bioprosthesis / Q000009:adverse effects; D003094:Collagen / Q000648:ultrastructure; D004617:Embolism / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D010496:Pericardium / Q000473:pathology; D011475:Prosthesis Failure; D012086:Reoperation; D015996:Survival Rate
D003094:Collagen